Natera, Inc. (NTRA)
USD 156.66
(3.5%)
USD 156.66
(3.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 441.99 Million USD | 0.78% |
| 2022 | 438.58 Million USD | 12.03% |
| 2021 | 391.48 Million USD | 42.98% |
| 2020 | 273.79 Million USD | 82.44% |
| 2019 | 150.07 Million USD | 21.51% |
| 2018 | 123.51 Million USD | 0.27% |
| 2017 | 123.17 Million USD | 148.22% |
| 2016 | 49.62 Million USD | 17.9% |
| 2015 | 42.09 Million USD | 56.97% |
| 2014 | 26.81 Million USD | 10.31% |
| 2013 | 24.3 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 437.6 Million USD | -0.5% |
| 2024 Q1 | 439.79 Million USD | -0.5% |
| 2023 FY | 441.99 Million USD | 0.78% |
| 2023 Q2 | 433.8 Million USD | -0.55% |
| 2023 Q3 | 431.34 Million USD | -0.57% |
| 2023 Q1 | 436.22 Million USD | -2.24% |
| 2023 Q4 | 441.99 Million USD | 2.47% |
| 2022 Q4 | 446.21 Million USD | 7.24% |
| 2022 Q3 | 416.09 Million USD | 3.46% |
| 2022 FY | 438.58 Million USD | 12.03% |
| 2022 Q1 | 403.47 Million USD | 1.57% |
| 2022 Q2 | 402.15 Million USD | -0.33% |
| 2021 FY | 391.48 Million USD | 42.98% |
| 2021 Q1 | 380.33 Million USD | 35.31% |
| 2021 Q2 | 379.34 Million USD | -0.26% |
| 2021 Q3 | 378.52 Million USD | -0.22% |
| 2021 Q4 | 397.23 Million USD | 4.94% |
| 2020 Q4 | 281.09 Million USD | 3.55% |
| 2020 Q2 | 270.64 Million USD | 83.25% |
| 2020 Q1 | 147.69 Million USD | -1.59% |
| 2020 FY | 273.79 Million USD | 82.44% |
| 2020 Q3 | 271.45 Million USD | 0.3% |
| 2019 Q4 | 150.07 Million USD | -0.97% |
| 2019 FY | 150.07 Million USD | 21.51% |
| 2019 Q3 | 151.53 Million USD | -0.91% |
| 2019 Q2 | 152.93 Million USD | -0.86% |
| 2019 Q1 | 154.25 Million USD | 24.9% |
| 2018 Q4 | 123.51 Million USD | 0.07% |
| 2018 FY | 123.51 Million USD | 0.27% |
| 2018 Q1 | 123.26 Million USD | 0.07% |
| 2018 Q2 | 123.34 Million USD | 0.06% |
| 2018 Q3 | 123.41 Million USD | 0.06% |
| 2017 FY | 123.17 Million USD | 148.22% |
| 2017 Q4 | 123.17 Million USD | -0.1% |
| 2017 Q3 | 123.29 Million USD | 146.49% |
| 2017 Q2 | 50.02 Million USD | 0.43% |
| 2017 Q1 | 49.8 Million USD | 0.37% |
| 2016 Q3 | 49.47 Million USD | 0.3% |
| 2016 Q2 | 49.32 Million USD | 16.87% |
| 2016 Q1 | 42.2 Million USD | 0.27% |
| 2016 Q4 | 49.62 Million USD | 0.31% |
| 2016 FY | 49.62 Million USD | 17.9% |
| 2015 Q4 | 42.09 Million USD | 97.83% |
| 2015 Q3 | 21.27 Million USD | -23.37% |
| 2015 Q2 | 27.76 Million USD | -0.94% |
| 2015 FY | 42.09 Million USD | 56.97% |
| 2015 Q1 | 28.02 Million USD | 4.53% |
| 2014 FY | 26.81 Million USD | 10.31% |
| 2014 Q1 | 25.52 Million USD | 5.03% |
| 2014 Q3 | 22.56 Million USD | 0.0% |
| 2014 Q4 | 26.81 Million USD | 18.82% |
| 2013 FY | 24.3 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 24.3 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 426 Thousand USD | -103654.225% |
| Applied DNA Sciences, Inc. | 1.23 Million USD | -35609.104% |
| Aspira Women's Health Inc. | 2.26 Million USD | -19405.428% |
| Biodesix, Inc. | 60.69 Million USD | -628.268% |
| BioNexus Gene Lab Corp. | 133.39 Thousand USD | -331241.505% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -27898.358% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -27898.358% |
| Bionano Genomics, Inc. | 87.94 Million USD | -402.567% |
| CareDx, Inc | 34.22 Million USD | -1191.584% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 15.31 Million USD | -2786.956% |
| DarioHealth Corp. | 29.54 Million USD | -1396.202% |
| Exact Sciences Corporation | 2.55 Billion USD | 82.699% |
| Fulgent Genetics, Inc. | 14.9 Million USD | -2865.003% |
| Guardant Health, Inc. | 1.35 Billion USD | 67.351% |
| ICON Public Limited Company | 3.93 Billion USD | 88.777% |
| IDEXX Laboratories, Inc. | 947.88 Million USD | 53.37% |
| Illumina, Inc. | 2.26 Billion USD | 80.46% |
| Intelligent Bio Solutions Inc. | 871.44 Thousand USD | -50619.843% |
| iSpecimen Inc. | 196.24 Thousand USD | -225126.249% |
| Standard BioTools Inc. | 98.21 Million USD | -350.049% |
| MDxHealth SA | 41.26 Million USD | -971.109% |
| 23andMe Holding Co. | 76.51 Million USD | -477.655% |
| Medpace Holdings, Inc. | 142.12 Million USD | -210.995% |
| Myriad Genetics, Inc. | 145 Million USD | -204.823% |
| Mainz Biomed B.V. | 7.42 Million USD | -5856.153% |
| ENDRA Life Sciences Inc. | 394.4 Thousand USD | -111966.338% |
| NeoGenomics, Inc. | 611.67 Million USD | 27.741% |
| Neogen Corporation | 906.23 Million USD | 51.228% |
| Inotiv, Inc. | 417.64 Million USD | -5.831% |
| OPKO Health, Inc. | 326.56 Million USD | -35.347% |
| Psychemedics Corporation | 2.29 Million USD | -19133.812% |
| Prenetics Global Limited | 2.36 Million USD | -18554.311% |
| Prenetics Global Limited | 2.36 Million USD | -18554.311% |
| Precipio, Inc. | 1.11 Million USD | -39505.108% |
| Personalis, Inc. | 48.96 Million USD | -802.727% |
| RadNet, Inc. | 1.49 Billion USD | 70.358% |
| Sera Prognostics, Inc. | 1.85 Million USD | -23688.644% |
| Sotera Health Company | 2.32 Billion USD | 81.006% |
| Neuronetics, Inc. | 62.47 Million USD | -607.483% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -12146.966% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -12146.966% |
| Trinity Biotech plc | 67.42 Million USD | -555.513% |
| Twist Bioscience Corporation | 94.06 Million USD | -369.86% |
| Exagen Inc. | 23.72 Million USD | -1763.298% |